Skip to main content

Table 2 (abstract P70). Overview of adverse events.

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

   Galcanezumab
Event Placebo
N=1451
n (%)
120-mg
N=705
n (%)
240-mg
N=730
n (%)
Combined
N=1435
n (%)
Deaths 0 0 0 0
SAE 14 (1.0) 12 (1.7) 11 (1.5) 23 (1.6)
DCAE 24 (1.7) 13 (1.8) 22 (3.0) 35 (2.4)
TEAE 827 (57.0) 441 (62.6) 472 (64.7) 913 (63.6)
  1. Abbreviations: SAE Serious adverse events, DCAE discontinuation due to an adverse event, TEAE Treatment-emergent adverse events
  2. Indicates P < .05 compared with placebo
  3. Indicates P < .001 compared with placebo